Segments (Tables)

9 Months Ended

Sep. 30, 2020

Information by reportable segment was as follows:


	Three Months Ended September 30, 2020
	PGEN Therapeutics		ActoBio		MBP Titan		Trans Ova		Human Biotherapeutics		All Other		Total
Revenues from external customers	$	164	$	2,823	$	—	$	15,228	$	2,394	$	2,974	$	23,583
Intersegment revenues	1,992		—		—		55		—		—		2,047
Total segment revenues	$	2,156	$	2,823	$	—	$	15,283	$	2,394	$	2,974	$	25,630

Segment Adjusted EBITDA	$	(6,739)	$	(1,602)	$	(1,765)	$	(1,606)	$	(420)	$	1,654	$	(10,478)


	Three Months Ended September 30, 2019
	PGEN Therapeutics		ActoBio		MBP Titan		Trans Ova		Human Biotherapeutics		All Other		Total
Revenues from external customers	$	444	$	231	$	1,117	$	13,981	$	402	$	2,124	$	18,299
Intersegment revenues	2,313		6		—		257		—		72		2,648
Total segment revenues	$	2,757	$	237	$	1,117	$	14,238	$	402	$	2,196	$	20,947

Segment Adjusted EBITDA	$	(5,953)	$	(4,634)	$	(9,024)	$	(5,560)	$	(142)	$	(1,345)	$	(26,658)


	Nine Months Ended September 30, 2020
	PGEN Therapeutics		ActoBio		MBP Titan		Trans Ova		Human Biotherapeutics		All Other		Total
Revenues from external customers	$	542	$	3,053	$	—	$	55,858	$	16,967	$	7,371	$	83,791
Intersegment revenues	5,707		(3)		7		254		—		281		6,246
Total segment revenues	$	6,249	$	3,050	$	7	$	56,112	$	16,967	$	7,652	$	90,037

Segment Adjusted EBITDA	$	(19,356)	$	(4,727)	$	(15,728)	$	3,723	$	(2,253)	$	2,783	$	(35,558)


	Nine Months Ended September 30, 2019
	PGEN Therapeutics		ActoBio		MBP Titan		Trans Ova		Human Biotherapeutics		All Other		Total
Revenues from external customers	$	2,174	$	813	$	3,813	$	53,307	$	3,247	$	10,219	$	73,573
Intersegment revenues	7,090		501		2		1,204		—		145		8,942
Total segment revenues	$	9,264	$	1,314	$	3,815	$	54,511	$	3,247	$	10,364	$	82,515

Segment Adjusted EBITDA	$	(20,789)	$	(11,196)	$	(26,238)	$	(2,854)	$	(719)	$	(5,062)	$	(66,858)

The table below reconciles total segment revenues from reportable segments to total consolidated revenues:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Total segment revenues from reportable segments	$	22,656	$	18,751	$	82,385	$	72,151
Other revenues, including from other operating segments	2,974		2,196		8,714		10,511
Elimination of intersegment revenues	(2,047)		(2,648)		(7,254)		(8,942)
Total consolidated revenues	$	23,583	$	18,299	$	83,845	$	73,720

The table below reconciles Segment Adjusted EBITDA for reportable segments to consolidated net loss from continuing operations before income taxes:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
Segment Adjusted EBITDA for reportable segments	$	(12,132)	$	(25,313)	$	(38,341)	$	(61,796)
All Other Segment Adjusted EBITDA	1,654		(1,345)		2,783		(5,062)
Remove cash paid for capital expenditures and investments in affiliates	984		4,869		5,604		12,536
Add recognition of previously deferred revenue associated with upfront and milestone payments	7,132		3,957		25,178		14,816
Other expenses:
Interest expense	(4,646)		(4,466)		(13,830)		(13,124)
Depreciation and amortization	(4,108)		(4,764)		(13,701)		(14,971)
Impairment losses	(920)		(626)		(22,961)		(626)

Stock-based compensation expense	(4,600)		(4,805)		(15,215)		(12,569)
Adjustment related to bonuses paid in equity awards	—		—		2,833		—
Equity in net loss of affiliates	(523)		(479)		(1,125)		(1,943)
Other	4		35		16		35
Unallocated corporate costs	(10,412)		(13,028)		(27,938)		(42,476)
Eliminations	(1,991)		(3,092)		(6,237)		(9,104)
Consolidated net loss from continuing operations before income taxes	$	(29,558)	$	(49,057)	$	(102,934)	$	(134,284)